Report from BioJapan: Nordic biotech on the long game in Japan

The Nordic companies arrives in Yokohama with different assets and aims, yet much of what they say about Japan overlaps.

For NextCell Pharma, the trip is about finding partners for NXTCL-T1D, its allogeneic cell therapy in type 1 diabetes, and specifically companies that can contribute strategically and financially to its pivotal programme aimed at Japan.